Skip to main content
SpringerLink
Log in

Statins and Menopause

  • Leading Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

During the reproductive period, women generally have lower low-density lipoprotein (LDL) cholesterol and higher high-density lipoprotein cholesterol than age- and diet-matched men. However, these possibly antiatherogenic characteristics of lipoproteins are changed to a potentially atherogenic profile after menopause. Menopause-related changes in lipoprotein profile can be corrected by the administration of hormone replacement therapy (HRT). However, the results of recent studies did not show definite benefits of HRT on coronary heart disease-related mortality rates. On the other hand, several large-scale, long-term clinical trials provide evidence for efficacy and safety of HMG-CoA reductase inhibitors (statins) in both men and women. The results of 19 short-term clinical trials using simvastatin, pravastatin, fluvastatin or lovastatin in postmenopausal women are summarised and discussed. All these investigations reported significant reductions in both total and LDL cholesterol levels. The question of whether statin therapy results in a significant decrease in cardiovascular-related mortality rates along with a better quality of life in postmenopausal women remains to be investigated in large-scale, randomised, double-blind, placebo-controlled clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316: 1105–10

    Article  PubMed  CAS  Google Scholar 

  2. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses’s Health Study. N Engl J Med 1991; 325: 756–62

    Article  PubMed  CAS  Google Scholar 

  3. Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47–63

    Article  PubMed  CAS  Google Scholar 

  4. American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med 1992; 117: 1038–41

    Google Scholar 

  5. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589–93

    Article  PubMed  CAS  Google Scholar 

  6. Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med 1994; 330: 1062–71

    Article  PubMed  CAS  Google Scholar 

  7. Brown SA, Hutchinson R, Morrisett JD, et al. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities: the Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb 1993; 13: 1139–58

    Article  PubMed  CAS  Google Scholar 

  8. Kannel WB. Prospects for prevention of cardiovascular disease in the elderly. Prev Cardiol 1998; 1: 32–9

    Google Scholar 

  9. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208

    Article  Google Scholar 

  10. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–204

    Article  PubMed  CAS  Google Scholar 

  11. Sacks FM, Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 1994; 5: 236–40

    Article  PubMed  CAS  Google Scholar 

  12. Collins P, Rosano GMC, Sarrel PM, et al. 17β-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995; 92: 24–30

    Article  PubMed  CAS  Google Scholar 

  13. Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994; 343: 269–70

    Article  PubMed  CAS  Google Scholar 

  14. Vargas R, Wroblewska B, Rego A, et al. Oestradiol inhibits smooth muscle proliferation of pig coronary artery. Br J Pharmacol 1993; 109: 612–7

    Article  PubMed  CAS  Google Scholar 

  15. Proudler AJ, Ahmed AIH, Crook D, et al. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 1995; 346: 89–90

    Article  PubMed  CAS  Google Scholar 

  16. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 605–13

    CAS  Google Scholar 

  17. Fak AS, Erenus M, Tezcan H, et al. Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on serum lipid levels in hypercholesterolemic postmenopausal women. Eur Heart J 2000; 21: 190–7

    Article  PubMed  CAS  Google Scholar 

  18. Darling GM, Johns JA, McCloud PI, et al. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337: 595–601

    Article  PubMed  CAS  Google Scholar 

  19. Nakajima K. Sex-related differences in response of plasma lipids to simvastatin: the Saitama Postmenopausal Lipid Intervention Study. S-POLIS Group. Clin Ther 1999; 21: 2047–57

    Article  CAS  Google Scholar 

  20. Ohmichi M, Ikegami H, Kurachi H, et al. Effects of bezafibrate and simvastatin on plasma lipoproteins in hypercholesterolemia resistant to hormone replacement therapy. Maturitas 2001; 38: 279–86

    Article  PubMed  CAS  Google Scholar 

  21. Sbarouni E, Kyriakides ZS, Kremastinos DTH. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998; 32: 1244–50

    Article  PubMed  CAS  Google Scholar 

  22. Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999; 99: 354–60

    Article  PubMed  CAS  Google Scholar 

  23. Wakatsuki A, Okatani Y, Ikenoue N. Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia. Atherosclerosis 2000; 150: 103–11

    Article  PubMed  CAS  Google Scholar 

  24. Wakatsuki A, Ikenoue N, Izumiya C, et al. Effect of estrogen and simvastatin on low-density lipoprotein subclasses in hypercholesterolemic postmenopausal women. Obstet Gynecol 1998; 92: 367–72

    Article  PubMed  CAS  Google Scholar 

  25. Averbuch M, Ayalon D, Eckstein N, et al. Hormone replacement and simvastatin in the therapy of hypercholesterolemic postmenopausal women. J Med 1998; 29: 343–50

    PubMed  CAS  Google Scholar 

  26. Gavish D, Leibovitz E, Shapira I, et al. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: Efficacy and safety. J Intern Med 2000; 247: 563–9

    Article  PubMed  CAS  Google Scholar 

  27. Ozsener S, Sendag F, Koc T, et al. A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women. J Obstet Gynecol Res 2001; 27: 353–8

    Article  CAS  Google Scholar 

  28. Lemay A, Dodin S, Turcot L, et al. Estrogen/progesterone replacement versus pravastatin and their sequential association in hypercholesterolemic postmenopausal women. Maturitas 2001; 40: 247–57

    Article  PubMed  CAS  Google Scholar 

  29. Ushiroyama T, Ikeda A, Ueki M. Beneficial effects of pravastatin in pre- and post-menopausal hyperlipidemic women: a 5 year study on serum lipid and sex hormone levels. Maturitas 2001; 37: 201–8

    Article  PubMed  CAS  Google Scholar 

  30. Davidson MH, Testolin LM, Maki KC, et al. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997; 157: 1186–92

    Article  PubMed  CAS  Google Scholar 

  31. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restonosis after successful coronary ballon angioplasty. Eur Heart J 1999; 20: 58–69

    Article  PubMed  CAS  Google Scholar 

  32. Marz W, Scharnagl H, Abletshauser C, et al. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 2001; 103: 1942–8

    Article  PubMed  CAS  Google Scholar 

  33. Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAP/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 2001; 10: 971–81

    Article  PubMed  CAS  Google Scholar 

  34. Bradford HB, Downton M, Chremos AN, et al. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia. Ann Intern Med 1993; 118: 850–5

    PubMed  CAS  Google Scholar 

  35. Herrington DM, Werbel BL, Riley WA, et al. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999; 33: 2030–7

    Article  PubMed  CAS  Google Scholar 

  36. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of stains and the subsequent development of deep vein thrombosis. Arch Intern Med 2001; 161: 1405–10

    Article  PubMed  CAS  Google Scholar 

  37. Sbarouni E, Melissari E, Kyriakides ZS, et al. Effects of simvastatin or hormone replacement therapy, or both, on fibrinogen, factor VII, and plasminogen activator inhibitor levels in postmenopausal women with proven coronary artery disease. Am J Cardiol 2000; 86: 80–3

    Article  PubMed  CAS  Google Scholar 

  38. Raggi P, Callister TQ, Davidson M, et al. Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. Am Heart J 2001; 141: 722–6

    Article  PubMed  CAS  Google Scholar 

  39. Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76–82

    Article  PubMed  CAS  Google Scholar 

  40. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme a: reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126–31

    Article  PubMed  Google Scholar 

  41. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97(12): 1129–35

    Article  PubMed  CAS  Google Scholar 

  42. Rikitake Y, Kawashima S, Takeshita S, et al. Antioxidant properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001; 154: 87–96

    Article  PubMed  CAS  Google Scholar 

  43. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004–110

    Article  PubMed  CAS  Google Scholar 

  44. Yang Z, Kozai T, van der Loo B, et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol 2000; 36: 1691–7

    Article  PubMed  CAS  Google Scholar 

  45. Moghadasian MH, Frohlich JJ. Statins and bones. Can Med Assoc J 2001; 164: 803–5

    CAS  Google Scholar 

  46. Van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001; 285: 1850–5

    Article  PubMed  Google Scholar 

  47. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844–50

    Article  PubMed  CAS  Google Scholar 

  48. Vaughn CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1–10

    Article  Google Scholar 

  49. Niwa S, Totsuka T, Hayashi S. Inhibitor effect of fluvastatin, an HMG-CoA reductase inhibitor, on expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996; 18: 669–75

    Article  PubMed  CAS  Google Scholar 

  50. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in primary prevention of acute coronary events. N Engl J Med 2001: 344; 1959–65

    Article  PubMed  CAS  Google Scholar 

  51. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999; 100: 230–5

    Article  PubMed  CAS  Google Scholar 

  52. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–43

    Article  PubMed  CAS  Google Scholar 

  53. Koh KK, Schenke WH, Waclawiw MA, et al. Statin attenuates increases in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation 2002; 105: 1531–3

    Article  PubMed  CAS  Google Scholar 

  54. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo and in vitro. Circulation 2001; 103: 276–383

    Article  PubMed  CAS  Google Scholar 

  55. Schror K. Platelet reactivity and arachidonic acid metabolism in type II hypercholesterolemia and its modification by cholesterol-lowering agents. Eicosanoids 1990; 3: 67–73

    PubMed  CAS  Google Scholar 

  56. Alfon J, Royo T, Garcia-Moll X, et al. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Arterioscler Thromb Vasc Biol 1999; 19: 1812–7

    Article  PubMed  CAS  Google Scholar 

  57. Koh KK. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol 2000; 76: 23–32

    Article  PubMed  CAS  Google Scholar 

  58. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9

    Google Scholar 

  59. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 1996; 335: 1001–9

    CAS  Google Scholar 

  60. LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study group. N Engl J Med 1998; 339: 1349–57

    Article  Google Scholar 

  61. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study. JAMA 1998; 279: 1615–22

    CAS  Google Scholar 

  62. Moghadasian MH, Mancini GBJ, Frohlich JJ. Pharmacotherapy of hypercholesterolemia: statins in clinical practice. Exp Opin Pharmacother 2000; 1: 683–95

    Article  CAS  Google Scholar 

  63. Moghadasian MH. Clinical pharmacology of 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors. Life Sci 1999; 65: 1329–37

    Article  PubMed  CAS  Google Scholar 

  64. Soma MR, Osnago-Gadda I, Paoletti R, et al. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993; 153: 1462–8

    Article  PubMed  CAS  Google Scholar 

  65. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation 1993; 87: 1135–41

    Article  PubMed  CAS  Google Scholar 

  66. The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative Clinical Trial and Observational Study. Controlled Clin Trials 1998; 19: 61–109

    Article  Google Scholar 

  67. Kmietowicz Z. Women’s health study signs up million women. BMJ 2000; 321: 981

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This is an invited review article. No particular source of funding was designated for the preparation of this paper. The author has no conflicts of interest relevant to the contents of the paper.

Author information

Authors and Affiliations

  1. Division of Clinical Trials, PhenoPharma Research Inc., and Department of Pathology and Laboratory Medicine, The University of British Columbia, Vancouver, British Columbia, Canada

    Mohammed H. Moghadasian

Authors
  1. Mohammed H. Moghadasian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammed H. Moghadasian.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moghadasian, M.H. Statins and Menopause. Drugs 62, 2421–2431 (2002). https://doi.org/10.2165/00003495-200262170-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200262170-00002

Keywords

Search

Navigation